GlassScriptPhysician profile
Connie L Celum
NPI 1124185319
$57,400.45
in general payments reported to CMS, 2019-2025
5 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,014 · 2020: $1,700 · 2021: $3,188 · 2022: $19K · 2023: $6,966 · 2024: $5,767 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Travel and Lodging: $1,589 · Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,293.98 |
| Travel and Lodging | $1,588.62 |
| Food and Beverage | $551.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $44,288.98 | 2019-2025 | |
| Viiv Healthcare Company | $6,966.48 | 2023 | |
| Gilead Sciences, INC. | $3,244.99 | 2019-2025 | |
| Roche Diagnostics Corporation | $2,900.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connie Celum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.